Scientists have found that insulin has met an evolutionary cul-de-sac, limiting its ability to adapt to obesity and thereby rendering most people vulnerable to Type 2 diabetes. A recent study from scientists at Indiana University School of Medicine, the University of Michigan and Case Western Reserve University has determined that the sequence of insulin has become entrenched at the edge of impaired production, an intrinsic vulnerability unmasked by rare mutations in the insulin gene causing diabetes in childhood
Indiana University School of Medicine researchers are participating in the Rare and Atypical Diabetes Network (RADIANT), a nationwide study funded by the National Institutes of Health. The study seeks to discover new forms of diabetes, identify their causes, and understand how they differ from more common types of diabetes.
Indiana University School of Medicine is leading the first study of the national Diabetic Foot Consortium with the goal of preventing reopening of closed wounds by identifying a biomarker that would predict such recurrence during the process of standard wound care.
INDIANAPOLIS—Carmella Evans-Molina, MD, PhD, has been appointed director of the Center for Diabetes and Metabolic Diseases (CDMD) at Indiana University School of Medicine. Evans-Molina is the center’s second appointed director since it received designation from the National Institutes of Health in 2015. The center’s mission is to bring cutting-edge research tools to diabetes investigators at […]
It is well understood that people with diabetes have an increased risk for a number of other health complications—including cancer. Last year, when Indiana University School of Medicine researchers demonstrated that inflammation can increase risk for leukemia, they wondered if it was also the culprit that placed people with diabetes at a higher risk for […]
A set of clinical trials examining youth and adults with type 2 diabetes or impaired glucose tolerance has found that disease progression in adults slowed during medical treatment but resumed after treatment stopped. Youth on the same treatment had markedly poorer outcomes with continued disease progression both during and after the treatment. This research, funded […]
Presented on June 9 in San Francisco at the 2019 American Diabetes Association’s 79th Scientific Sessions and published in the New England Journal of Medicine, findings from TrialNet’s Teplizumab (anti-CD3) Prevention Study show a drug that targets the immune system can delay Type 1 diabetes a median of 2 years in children and adults at […]